Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bill Arana"'
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 440-446 (2023)
Checkpoint inhibitors (CIs) are now standard of care for late-stage non-small-cell lung cancer (NSCLC); however, only a minority of patients treated with a CI show clinical benefit compared to platinum-based chemotherapy alone, regardless of programm
Externí odkaz:
https://doaj.org/article/c073b8672bd74df380eeb6911c75f383
Autor:
Daniel Morgensztern, Xiaoxing Cui, Toana Kawashima, Bill Arana, George E. Peoples, Rachel E. Sanborn, Nathan A. Pennell, Wael A. Harb, Roger B. Cohen, Lyudmila Bazhenova
Publikováno v:
Journal of Clinical Oncology. 39:9100-9100
9100 Background: Viagenpumatucel-L (HS-110) is an allogeneic cell therapy derived from a human lung adenocarcinoma cell line incorporating multiple cancer testis antigens and transfected with a gp96-Ig fusion protein. Methods: We report interim resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7ff2281b091855584c909263c9f4ed6
https://doi.org/10.1200/jco.2021.39.15_suppl.9100
https://doi.org/10.1200/jco.2021.39.15_suppl.9100
Publikováno v:
The Journal of Clinical Pharmacology. 51:1302-1309
Warfarin, an antagonist of vitamin K, which inhibits clotting factor synthesis, is prescribed for thrombosis prophylaxis and treatment and is known to have a narrow therapeutic range. Pitavastatin is a potent HMG-CoA reductase inhibitor. In this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b97a4b25b398791e31c1188631f55f4
https://doi.org/10.1177/0091270010379811
https://doi.org/10.1177/0091270010379811